戻る
Recursion Pharmaceuticals Inc (RXRX)価格
RXRX 株価推移チャート
RXRX 収入
Recursion Pharmaceuticals Inc
$3.96
-0.5%
$-0.02
本日現在の状況：Feb 09, 15:29:20 GMT-5
最新の利益結果: Q3 '25
報告済み: 2025-11-05
歴史的収益
四半期
年次
EPS
収入
Earnings FAQ
RXRXの最近の1株当たり利益（EPS）は予想と比較してどうでしたか？
Recursion Pharmaceuticals Inc RXRXの前四半期の収益はどうでしたか？
Recursion Pharmaceuticals Incの収益見積もりはいくらですか？
Recursion Pharmaceuticals Incの収益品質スコアはどれくらいですか？
Recursion Pharmaceuticals Incはいつ収益を報告しますか？
Recursion Pharmaceuticals Incの予想収益はいくらですか？
Recursion Pharmaceuticals Incは収益予想を上回りましたか？
主要データ
前終値
$3.98
始値
$3.96
当日レンジ
$3.85 - $4
52週レンジ
$3.54 - $12.36
取引高
11.4M
平均取引高
23.2M
1株当たり利益(TTM)
-1.81
配当利回り
--
時価総額
$2.0B
RXRXとは何ですか？
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. The company is headquartered in Salt Lake City, Utah and currently employs 840 full-time employees. The company went IPO on 2021-04-16. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The firm integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.